Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.42 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.40 |
| ▸ | LPAR5 | Q9H1C0 | 6/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1336121 | 0.98 | PKM (0.41) | PKMHDAC1HDAC6TAS2R14LPAR1 | |
| SCHEMBL3372477 | 0.77 | HDAC1 (0.58) | PKMHDAC1HDAC6TAS2R14LPAR1 | |
| SCHEMBL5722085 | 0.72 | HDAC1 (0.53) | PKMHDAC1HDAC6TAS2R14LPAR1 | |
| SCHEMBL5722086 | 0.72 | HDAC1 (0.53) | PKMHDAC1HDAC6TAS2R14LPAR1 | |
| SCHEMBL393116 | 0.71 | HDAC1 (0.52) | PKMHDAC1HDAC6TAS2R14LPAR1 | |
| SCHEMBL5030087 | 0.71 | HDAC1 (0.52) | PKMHDAC1HDAC6TAS2R14LPAR1 | |
| SCHEMBL21400325 | 0.70 | HDAC1 (0.55) | PKMHDAC1HDAC6LPAR1LPAR5 | |
| SCHEMBL8773484 | 0.70 | HDAC1 (0.61) | PKMHDAC1HDAC6LPAR1LPAR5 | |
| SCHEMBL1335570 | 0.68 | HDAC1 (0.37) | HDAC1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL1665701 | 0.68 | MEN1 (0.41) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110275678-A1 | New Pyridine Derivatives as Leptin Receptor Modulator Mimetics | BIOVITRUM AB (SE) | 2011-11-10 | — | — | US | claimed |
| EP-2313094-A1 | NEW PYRIDINE DERIVATIVES AS LEPTIN RECEPTOR MODULATOR MIMETICS | AstraZeneca AB (SE) | 2011-04-27 | — | — | EP | claimed |
| US-20110275678-A1 | New Pyridine Derivatives as Leptin Receptor Modulator Mimetics | BIOVITRUM AB (SE) | 2011-11-10 | — | — | US | disclosed |
| EP-2313094-A1 | NEW PYRIDINE DERIVATIVES AS LEPTIN RECEPTOR MODULATOR MIMETICS | AstraZeneca AB (SE) | 2011-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275678-A1 | New Pyridine Derivatives as Leptin Receptor Modulator Mimetics | GPR119, GLP1R, ADIPOR1 | PKM 821/4885HDAC1 457/4885HDAC6 3176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.